Green Leaf Pharmaceuticals: Complete issuance of $180 million 5.25% convertible bonds maturing in 2031.

Green Leaf Pharmaceuticals announced on June 11th that the company has completed the issuance of $180,000,000 5.25% convertible bonds due in 2031 on the Hong Kong Stock Exchange. The Board of Directors announced that all the preconditions for the issuance of the bonds as stated in the subscription agreement have been met, and the total principal amount of $180,000,000 bonds was completed on June 10, 2026. The bonds were listed on the Vienna Stock Exchange on June 10, 2026. The initial conversion price per share is HK$2.71, at a premium of approximately 24.9% over the closing market price of HK$2.170 on the Hong Kong Stock Exchange on June 3, 2026, and a premium of approximately 24.1% over the average closing price of HK$2.184 per share on the last five consecutive trading days on the Hong Kong Stock Exchange until June 2, 2026. Listing and trading approval for the conversion shares has been granted by the Hong Kong Stock Exchange. The company intends to use the net proceeds of approximately $177.2 million from this bond issuance for refinancing existing debts and general corporate purposes.